Provided by Tiger Trade Technology Pte. Ltd.

Cartesian Therapeutics

5.85
-0.2300-3.78%
Post-market: 5.850.00000.00%16:18 EDT
Volume:321.74K
Turnover:1.87M
Market Cap:155.08M
PE:-1.17
High:6.17
Open:6.08
Low:5.60
Close:6.08
52wk High:15.57
52wk Low:5.60
Shares:26.51M
Float Shares:9.79M
Volume Ratio:2.35
T/O Rate:3.29%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.0200
EPS(LYR):-4.4814
ROE:-7029.26%
ROA:-14.82%
PB:-1.23
PE(LYR):-1.31

Loading ...

Cartesian Pauses Lupus And Multiple Myeloma Studies As It Shifts Development Focus

Benzinga
·
Nov 15, 2025

Wedbush Remains a Buy on Cartesian Therapeutics (RNAC)

TIPRANKS
·
Nov 15, 2025

Top Calls on Wall Street: Nvidia, Applied Materials, Nu Holdings, Lowe's, Shake Shack, Gap & More

Tiger Newspress
·
Nov 15, 2025

Strategic Realignment Boosts Cartesian Therapeutics’ Prospects: Gil Blum Issues Buy Rating

TIPRANKS
·
Nov 14, 2025

Cartesian Therapeutics Is Maintained at Buy by BTIG

Dow Jones
·
Nov 14, 2025

Cartesian Therapeutics price target raised to $44 from $42 at BTIG

TIPRANKS
·
Nov 14, 2025

Cartesian Therapeutics Reports Q3 2025 Financial Results

TIPRANKS
·
Nov 14, 2025

Cartesian Therapeutics Reports Promising Phase 2 Trial Results

TIPRANKS
·
Nov 14, 2025

Cartesian Therapeutics Inc - Cartesian Plans to Pause Further Development of Descartes-08 in Sle

THOMSON REUTERS
·
Nov 14, 2025

Cartesian: Myositis Seamless Adaptive Clinical Trial Design Provides Potential Opportunity for Single Pivotal Trial Expected to Commence in 1H26

THOMSON REUTERS
·
Nov 14, 2025

Cartesian - 100% Lldas Response Rate Observed in Patients With Sle Who Got Descartes-08 in Phase 2 Open-Label Trial Reaching Month 3 Follow-up

THOMSON REUTERS
·
Nov 14, 2025

Cartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Trial of Descartes-08 in Patients with SLE and Expansion of Clinical Development into Myositis

GlobeNewswire
·
Nov 14, 2025

Recent 11% pullback would hurt Cartesian Therapeutics, Inc. (NASDAQ:RNAC) insiders

Simply Wall St.
·
Nov 11, 2025

Analysts Offer Insights on Healthcare Companies: Doximity (DOCS), Cartesian Therapeutics (RNAC) and Anixa Biosciences (ANIX)

TIPRANKS
·
Nov 07, 2025

Needham Sticks to Their Buy Rating for Cartesian Therapeutics (RNAC)

TIPRANKS
·
Nov 07, 2025

Cartesian Therapeutics Q3 EPS $(1.38) Misses $(0.84) Estimate, Sales $452.000K Beat $243.500K Estimate

Benzinga
·
Nov 06, 2025

Cartesian Therapeutics reports Q3 EPS ($1.38) vs ($1.13) last year

TIPRANKS
·
Nov 06, 2025

Cartesian Therapeutics About $145.1 Mln Cash, Cash Equivalents & Restricted Cash at Sept 30, Expected to Support Planned Operations Into Mid-2027

THOMSON REUTERS
·
Nov 06, 2025

Cartesian Therapeutics Inc expected to post a loss of 84 cents a share - Earnings Preview

Reuters
·
Nov 03, 2025

Cartesian Therapeutics Announces New Employment Inducement Grants

GlobeNewswire
·
Oct 30, 2025